174 related articles for article (PubMed ID: 35456161)
1. Dysthyroid Optic Neuropathy: Treatment with Additional Intravenous Methylprednisolone Pulses after the Basic Schedule Is Associated with Stabilization or Further Improvement of Clinical Outcome.
Pelewicz M; Rymuza J; Pelewicz K; Miśkiewicz P
J Clin Med; 2022 Apr; 11(8):. PubMed ID: 35456161
[TBL] [Abstract][Full Text] [Related]
2. A single-center analysis of visual outcomes and associated factors after intravenous methylprednisolone treatment for dysthyroid optic neuropathy.
Kemchoknatee P; Tangon D; Srisombut T
BMC Ophthalmol; 2023 Jan; 23(1):32. PubMed ID: 36690985
[TBL] [Abstract][Full Text] [Related]
3. Complete recovery of visual acuity as the main goal of treatment in patients with dysthyroid optic neuropathy.
Miśkiewicz P; Rutkowska B; Jabłońska A; Krzeski A; Trautsolt-Jeziorska K; Kęcik D; Milczarek-Banach J; Pirko-Kotela K; Samsel A; Bednarczuk T
Endokrynol Pol; 2016; 67(2):166-73. PubMed ID: 26884288
[TBL] [Abstract][Full Text] [Related]
4. Sight-threatening Graves' orbitopathy: Twenty years' experience of a multidisciplinary thyroid-eye outpatient clinic.
Tramunt B; Imbert P; Grunenwald S; Boutault F; Caron P
Clin Endocrinol (Oxf); 2019 Jan; 90(1):208-213. PubMed ID: 30339291
[TBL] [Abstract][Full Text] [Related]
5. High dose intravenous methylprednisolone pulse therapy causes transient increase of serum calcium and phosphate levels.
Rymuza J; Popow M; Bednarczuk T; Miśkiewicz P
Pol Merkur Lekarski; 2019 Sep; 47(279):91-94. PubMed ID: 31557136
[TBL] [Abstract][Full Text] [Related]
6. Dysthyroid optic neuropathy: emerging treatment strategies.
Pelewicz-Sowa M; Miśkiewicz P
J Endocrinol Invest; 2023 Jul; 46(7):1305-1316. PubMed ID: 36802028
[TBL] [Abstract][Full Text] [Related]
7. Influence of Methylprednisolone Pulse Therapy on Liver Function in Patients with Graves' Orbitopathy.
Miśkiewicz P; Jankowska A; Brodzińska K; Milczarek-Banach J; Ambroziak U
Int J Endocrinol; 2018; 2018():1978590. PubMed ID: 30420883
[TBL] [Abstract][Full Text] [Related]
8. Dysthyroid optic neuropathy: a case series at a tertiary ophthalmic referral centre.
Chung IY; Hardy TG; Khong JJ
Eye (Lond); 2024 Apr; 38(6):1168-1172. PubMed ID: 38081935
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic outcomes of high-dose intravenous steroids in the treatment of dysthyroid optic neuropathy.
Currò N; Covelli D; Vannucchi G; Campi I; Pirola G; Simonetta S; Dazzi D; Guastella C; Pignataro L; Beck-Peccoz P; Ratiglia R; Salvi M
Thyroid; 2014 May; 24(5):897-905. PubMed ID: 24417307
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of Grave's ophthalmopathy with high doses of corticosteroids].
Cirić J; Zarković M; Stojanović M; Pepenezić Z; Randjelović G; Gligorović M; Trbojević B; Drezgić M; Nesović M
Srp Arh Celok Lek; 2000; 128(5-6):179-83. PubMed ID: 11089418
[TBL] [Abstract][Full Text] [Related]
11. Clinical and Visual Outcomes of Dysthyroid Optic Neuropathy After Surgical Orbital Decompression.
Currò N; Guastella C; Pirola G; Calonghi B; Bottari de Castello A; Fazio MC; di Benedetto S; Minorini V; Daga M; Contarino A; Muller I; Arosio M; Viola F; Pignataro L; Salvi M
Thyroid; 2023 Jun; 33(6):743-751. PubMed ID: 37140534
[No Abstract] [Full Text] [Related]
12. Early efficacy of teprotumumab for the treatment of dysthyroid optic neuropathy: A multicenter study.
Sears CM; Wang Y; Bailey LA; Turbin R; Subramanian PS; Douglas R; Cockerham K; Kossler AL
Am J Ophthalmol Case Rep; 2021 Sep; 23():101111. PubMed ID: 34113737
[TBL] [Abstract][Full Text] [Related]
13. Acute dysthyroid optic neuropathy exacerbated by orbital radiotherapy.
Hersh D; Kinnar M
Orbit; 2014 Oct; 33(5):385-7. PubMed ID: 24841498
[TBL] [Abstract][Full Text] [Related]
14. [Therapeutic outcomes and influence factors of maximal orbital decompression in the treatment of severe dysthyroid optic neuropathy].
Wang Y; Li YY; Yang N; Ma R; Xiao LH
Zhonghua Yan Ke Za Zhi; 2017 Jun; 53(6):416-423. PubMed ID: 28606262
[TBL] [Abstract][Full Text] [Related]
15. Macular blood flow changes in dysthyroid optic neuropathy after high-dose intravenous pulse methylprednisolone (IVMP).
Fan SX; Liang JQ; Wang J; Zhou C; Zhou SY; Wang M; Zeng P
Photodiagnosis Photodyn Ther; 2024 Feb; 45():103935. PubMed ID: 38104706
[TBL] [Abstract][Full Text] [Related]
16. Blood Pressure Profile and N-Terminal-proBNP Dynamics in Response to Intravenous Methylprednisolone Pulse Therapy of Severe Graves' Orbitopathy.
Miskiewicz P; Milczarek-Banach J; Bednarczuk T; Opolski G; Glowczynska R
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30261581
[TBL] [Abstract][Full Text] [Related]
17. Insights into Current Management Strategies for Dysthyroid Optic Neuropathy: A Review.
Tagami M; Honda S; Azumi A
Clin Ophthalmol; 2022; 16():841-850. PubMed ID: 35330749
[TBL] [Abstract][Full Text] [Related]
18. Therapy With Intravenous Methylprednisolone Pulses Is Associated With Loss of Bone Microarchitecture in Trabecular Bone Score -Assessment Among Patients With Moderate-to-Severe Graves' Orbitopathy: A Pilot Study.
Rymuza J; Pelewicz K; Przedlacki J; Miśkiewicz P
Front Endocrinol (Lausanne); 2022; 13():893600. PubMed ID: 35909547
[TBL] [Abstract][Full Text] [Related]
19. Management of patients with dysthyroid optic neuropathy treated with intravenous corticosteroids and/or orbital decompression surgery.
Rezar-Dreindl S; Papp A; Baumann A; Neumayer T; Eibenberger K; Stifter E; Schmidt-Erfurth U
Graefes Arch Clin Exp Ophthalmol; 2022 Nov; 260(11):3683-3691. PubMed ID: 35731314
[TBL] [Abstract][Full Text] [Related]
20. RETROSPECTIVE ANALYSIS OF PATIENTS WITH GRAVES ORBITOPATHY TREATED BY PULSES OF METHYLPREDNISOLONE, WITH A FOCUS ON ADVERSE EVENTS.
Schovanek J; Cibickova L; Karhanova M; Kovarova D; Frysak Z; Karasek D
Endocr Pract; 2018 Jul; 24(7):652-657. PubMed ID: 30048166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
